Navigation Links
IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
Date:1/22/2013

MOUNTAIN VIEW, Calif., Jan. 22, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) reported preliminary revenues of approximately $9.2 million and $33.8 million for the fourth quarter and full year 2012, respectively.  Revenues in the fourth quarter exceeded the high end of the Company's prior guidance and were driven by a healthy uptick in sales of laser systems. Management had projected revenues to be between $8.4 million and $8.7 million in the 2012 fourth quarter.

CEO William M. Moore said, "We were very pleased to see strong sales growth in the fourth quarter of 2012 driven by increased demand for our laser systems, especially the IQ532 system with MicroPulse™ technology, which has been the central focus of recent marketing campaigns. While it is too early to call the strong growth in the period a trend, the sales organization has seen a positive response to a sharpened commercial message as well as the continued positive clinical data and accelerated adoption of MicroPulse technology."

The stronger than anticipated sales of laser systems also shifted the overall product mix toward capital equipment rather than higher margin consumable products. As a result, IRIDEX anticipates gross margins for the 2012 fourth quarter below the guidance range of 49% to 51%.

Moore continued, "During the fourth quarter, we also maintained excellent operating expense management and believe we will be close to guidance of $4.0 million for the period."

During the fourth quarter, the Company announced the FDA 510(k) and Conformité Européenne (CE) clearances of its TxCell™ Scanning Laser Delivery System and began shipping orders. The TxCell product saves significant time in a variety of laser photocoagulation procedures, including those using MicroPulse. The Company also entered into a license agreement with QUANTEL Medical that gives QUANTEL access to IRIDEX' MicroPulse technology, a further step towards making Fovea-friendly therapies using MicroPulse a new standard of care.

The Company also completed a tender offer in which it purchased 487,500 shares of its common stock at a purchase price of $4.10 per share during the fourth quarter. Total shares outstanding following the share buyback are estimated to be 8.5 million. Mr. Moore commented, "We were pleased with the success of the tender offer. It is one of the ways that we can achieve our goal of delivering shareholder value. We intend to continue to assess this option going forward and have $1 million in funds approved under our stock repurchase program yet to be utilized."

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's anticipated operating and financial results for the fiscal year 2012 fourth quarter and year end, the effectiveness and market acceptance of the TxCell Scanning Laser Delivery System and MicroPulse laser therapy,  IRIDEX' marketing and sales efforts, and the Company's future share repurchase plans. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2012, June 30, 2012, and September 29, 2012, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

IRIDEX has not filed the Form 10-K for the 2012 fiscal year. As a result, all financial results described in this press release should be considered preliminary, and are subject to change to reflect any necessary corrections or adjustments, or changes in accounting estimates, that are identified prior to the time the Company is in a position to complete these filings.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
2. IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
3. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
4. IRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock
5. IRIDEX Reports 2012 Third Quarter Results
6. IRIDEX Announces Third Quarter 2012 Conference Call and Release Date
7. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
8. IRIDEX Reports 2012 Second Quarter Results
9. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
10. IRIDEX Reports 2012 First Quarter Results
11. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
(Date:9/18/2017)... ALLENTOWN , Pa. and KALAMAZOO, Mich. ... Allentown, Penn. , and OptiMed Specialty Pharmacy ... a business partnership to offer a strategic hub service ... PMD Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, ... A spirometer is a medical device used ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):